ABLE: single-arm trial of nab-paclitaxel with ANTI-PD1 in advanced urothelial cancer.

Jason Brown,Stephanie Daignault,Zachery R. Reichert,Phillip L. Palmbos,Ajjai Alva

ABLE: single-arm trial of nab-paclitaxel with ANTI-PD1 in advanced urothelial cancer.

2020

Jason Brown
Stephanie Daignault
Zachery R. Reichert
Phillip L. Palmbos
Ajjai Alva

520Background: Anti-PD1 immune checkpoint inhibitor monotherapy is standard in cisplatin ineligible advanced urothelial cancer (aUC) patients (pts) that is PDL1 positive as well as in platinum refr...

Keywords:

Cancer
Pathology
Oncology
Cisplatin
Nab-paclitaxel
Immune checkpoint
Medicine
Internal medicine
anti pd1
immune checkpoint inhibitors
urothelial cancer
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations